Indication:Severe, treatment resistant morphoea
Rheumatoid arthritis, Juvenile idiopathic arthritis & Active psoriatic arthritis in adults
Abatacept is recommended as a treatment option through routine commissioning for adults and children 2 years and over with severe, treatment resistant morphoea within the criteria set out in the commissioning policy
NICE TA 375
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed.
Full information can be found at:http://www.nice.org.uk/guidance/ta375/resources/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed-82602790920133
January 2016 NICE technology appraisal guidance [TA373]